Sacubtril/valsartan in HFpEF and Maintenance Hemodialysis

Noriko Kuwae^1, and Masahiro Yamasato¹

¹Department of Hemodialysis, Yonabaru Central Hospital, Yonabaru, Okinawa Prefecture, Japan

Cite this paper

Noriko Kuwae and Masahiro Yamasato. Sacubtril/valsartan in HFpEF and Maintenance Hemodialysis. American Journal of Medical Case Reports. 2023; 11(2):14-15. doi: 10.12691/AJMCR-11-2-1

Abstract

The purpose of this report is to describe effectiveness and tolerability of medical treatment with sacubitril/valsartan in a patient treated with hemodialysis. We describe the case of a 68-year-old man with heart failure with ejection fraction more than 60%, that is HFpEF undergoing hemodialysis. He had several times heart failure due to diastolic dysfunction, he could tolerate a dose of 50/50mg, total 100mg daily. After initiation of sacubitril/valsartan, there was a symptomatic improvement with clear reduction NT-proBNP, left atrial dimension, E/e’ as well as EF. In conclusion, in this patient with diastoric dysfunction undergoing hemodialysis, treatment with sacubitril/valsartan was effective, safe, and improved heart failure symptoms.

Keywords

Sacubitril/valsartan, ARNI, heart failure, HFpEF, hemodialysis

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Bozukurt B, Coats AJ, Tsutsui H, et al: Universal definition and classification of heart failure. J Card Fail S, 2021.
[2]	Solomon SD et al: Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Eng J Med 381: 1609-1620, 2019.
[3]	Tsutui H et al: Acute and Chronic Heart Failure Treatment Japanese Guideline. 2021. [https://www.j-circ.or.jp/cms/wpcontent/uploads/2021/03/JCS2021_Tsutsui.pdf].
[4]	Alex Heyse: Sacubitril/Valsartan in heart failure and end-stage renal insufficiency. European Society of Cardiology Heart Failure: 1331-1333, 2019.
[5]	Seonhwa Lee: Sacubtril/Valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease: ESC Heart Fail: 7(3):1125-1129, 2020.
[6]	Feng Z. Pharmacokinetics and pharmacodynamics and pharmacodynamics of Sacubtril/Valsartan in maintenance hemodialysis patients with heart failure. Blood Purification: 51: 270-279, 2021.
[7]	Lihua Wang: Use of angiotensin receptor Neprilysin Inhibitor in patients on maintenance hemodialysis with reduced cardiac ejection fraction. IJKD: 15: 288-299, 2021.
[8]	Pingping Kong: The effect of Sacubitril/Valsartan in a dialysis patient with severe heart failure. Case Reports in Clinical Medicine: 10(7): 197-202, 2021.
[9]	Daimon Shoichiro: Effect of Saucbtril/Valsartan on cardiac function in hemodialysis patients, Letter to the editor. The Apher Dial: 1-2. 2021.